TRxADE HEALTH, Inc. (MEDS)
USD 7.59
(4.55%)
USD 7.59
(4.55%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.26 Million USD | -163.5% |
| 2022 | -2.75 Million USD | 47.91% |
| 2021 | -5.29 Million USD | -197.2% |
| 2020 | -1.78 Million USD | -414.71% |
| 2019 | 565.81 Thousand USD | 745.79% |
| 2018 | -87.61 Thousand USD | -122.18% |
| 2017 | 395.09 Thousand USD | 140.15% |
| 2016 | -984.02 Thousand USD | 0.31% |
| 2015 | -987.04 Thousand USD | 31.05% |
| 2014 | -1.43 Million USD | 31.31% |
| 2013 | -2.08 Million USD | -1282.76% |
| 2012 | -150.71 Thousand USD | 0.0% |
| 2008 | -28.49 Million USD | -101003.38% |
| 2007 | -28.18 Thousand USD | -223.05% |
| 2006 | -8725.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -5.49 Million USD | 11.24% |
| 2024 Q2 | -1.49 Million USD | 72.79% |
| 2023 Q4 | -6.19 Million USD | -632.75% |
| 2023 FY | -7.26 Million USD | -163.5% |
| 2023 Q1 | -347.4 Thousand USD | -25.04% |
| 2023 Q2 | -345.62 Thousand USD | 0.51% |
| 2023 Q3 | -845.14 Thousand USD | -144.53% |
| 2022 FY | -2.75 Million USD | 47.91% |
| 2022 Q4 | -277.83 Thousand USD | 31.74% |
| 2022 Q2 | -1.1 Million USD | -13.89% |
| 2022 Q3 | -407.03 Thousand USD | 63.1% |
| 2022 Q1 | -968.57 Thousand USD | -23.81% |
| 2021 Q3 | -1.29 Million USD | 49.56% |
| 2021 FY | -5.29 Million USD | -197.2% |
| 2021 Q4 | -782.32 Thousand USD | 39.64% |
| 2021 Q1 | -644.25 Thousand USD | 72.05% |
| 2021 Q2 | -2.56 Million USD | -298.85% |
| 2020 Q4 | -2.3 Million USD | -1681.0% |
| 2020 Q2 | -535.27 Thousand USD | -384.38% |
| 2020 Q1 | 188.22 Thousand USD | 152.71% |
| 2020 Q3 | 145.82 Thousand USD | 127.24% |
| 2020 FY | -1.78 Million USD | -414.71% |
| 2019 FY | 565.81 Thousand USD | 745.79% |
| 2019 Q4 | -357.09 Thousand USD | -300.78% |
| 2019 Q2 | 132.7 Thousand USD | -22.74% |
| 2019 Q1 | 171.75 Thousand USD | 155.47% |
| 2019 Q3 | 177.85 Thousand USD | 34.02% |
| 2018 Q2 | 31.44 Thousand USD | -68.15% |
| 2018 Q1 | 98.72 Thousand USD | -38.39% |
| 2018 Q4 | -309.61 Thousand USD | -437.17% |
| 2018 Q3 | 91.82 Thousand USD | 192.02% |
| 2018 FY | -87.61 Thousand USD | -122.18% |
| 2017 Q3 | 89.61 Thousand USD | 83.7% |
| 2017 FY | 395.09 Thousand USD | 140.15% |
| 2017 Q4 | 160.24 Thousand USD | 78.82% |
| 2017 Q2 | 48.78 Thousand USD | -65.51% |
| 2017 Q1 | 141.45 Thousand USD | -87.49% |
| 2016 Q2 | -1.01 Million USD | -227.17% |
| 2016 FY | -984.02 Thousand USD | 0.31% |
| 2016 Q3 | -791.9 Thousand USD | 21.86% |
| 2016 Q1 | -309.74 Thousand USD | 29.82% |
| 2016 Q4 | 1.13 Million USD | 242.82% |
| 2015 Q3 | -76.56 Thousand USD | -189.49% |
| 2015 FY | -987.04 Thousand USD | 31.05% |
| 2015 Q1 | -442.65 Thousand USD | -1.27% |
| 2015 Q2 | -26.44 Thousand USD | 94.03% |
| 2015 Q4 | -441.38 Thousand USD | -476.5% |
| 2014 Q2 | -300.03 Thousand USD | 12.91% |
| 2014 Q3 | -349.82 Thousand USD | -16.6% |
| 2014 Q1 | -344.51 Thousand USD | 75.96% |
| 2014 Q4 | -437.09 Thousand USD | -24.95% |
| 2014 FY | -1.43 Million USD | 31.31% |
| 2013 FY | -2.08 Million USD | -1282.76% |
| 2013 Q3 | -282.82 Thousand USD | -53.77% |
| 2013 Q1 | -184.23 Thousand USD | 0.0% |
| 2013 Q2 | -183.93 Thousand USD | 0.16% |
| 2013 Q4 | -1.43 Million USD | -406.67% |
| 2012 FY | -150.71 Thousand USD | 0.0% |
| 2009 Q3 | -4531.00 USD | -73.87% |
| 2009 Q1 | -18.87 Thousand USD | 99.93% |
| 2009 Q2 | -2606.00 USD | 86.2% |
| 2008 Q4 | -28.47 Million USD | -715824.56% |
| 2008 Q2 | -6462.00 USD | 8.73% |
| 2008 Q1 | -7080.00 USD | 17.66% |
| 2008 FY | -28.49 Million USD | -101003.38% |
| 2008 Q3 | -3978.00 USD | 38.44% |
| 2007 Q3 | -7256.00 USD | 38.06% |
| 2007 Q2 | -11.71 Thousand USD | -1795.47% |
| 2007 Q1 | -618.00 USD | 80.56% |
| 2007 FY | -28.18 Thousand USD | -223.05% |
| 2007 Q4 | -8598.00 USD | -18.5% |
| 2006 Q3 | -1578.00 USD | 59.96% |
| 2006 FY | -8725.00 USD | 0.0% |
| 2006 Q4 | -3179.00 USD | -101.46% |
| 2006 Q2 | -3941.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | -13.47 Million USD | 46.107% |
| BIMI International Medical Inc. | -15.33 Million USD | 52.646% |
| China Jo-Jo Drugstores, Inc. | -3.53 Million USD | -105.497% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 580 Thousand USD | 1352.311% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 431 Thousand USD | 1785.245% |
| Leafly Holdings, Inc. | -7.05 Million USD | -3.012% |
| Leafly Holdings, Inc. | -7.05 Million USD | -3.012% |
| LifeMD, Inc. | -14.48 Million USD | 49.87% |
| LifeMD, Inc. | -14.48 Million USD | 49.87% |
| PetMed Express, Inc. | -8.16 Million USD | 11.009% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.948% |